After trying into Vaxzevria, the AstraZeneca/Oxford vaccine, the European Medicines Company (EMA) is now investigating the Johnson & Johnson vaccine for a attainable hyperlink to the prevalence of blood clots. This comes simply shortly earlier than its anticipated rollout on the continent.
EMA’s “Pharmovigilance Danger Evaluation Committee (Prac) had “launched a research” meant “to evaluate info on thromboembolic incidents” involving individuals who have obtained the Johnson & Johnson vaccine, in line with the statement.
Three of those circumstances have been present in US after native authorities had accepted the vaccine.
A fourth one -in an unnamed country- resulted within the dying of an individual throughout a check part.
The European Union member states will begin receiving the J&J vaccines “within the coming weeks,” greater than a month after the jab was formally accepted.
It’s the fourth vaccine to get EMA approval, after the Pfizer-BioNTech, Moderna and AstraZeneca/Oxford jabs. At present, solely the US and South Africa are actively administering the vaccine, whereas its use was accepted by Canada as properly.
In an effort to meet demand, Johnson & Johnson has in current months made agreements with laboratories and subcontractors in Europe, together with Sanofi in France, Catalent in Italy, and IDT Biologika in Germany.
French President targets 250 million doses
In the meantime, on Wednesday, EMA had said that blood clots have been a “very uncommon” facet impact of the AstraZeneca vaccine towards Covid-19 (now often called Vaxzevria), declaring that that the profit / threat ratio stays “optimistic”.
Nevertheless, France’s prime well being physique, the HAS, on Friday formally really helpful that folks beneath the age of 55 who obtained a primary injection of the AstraZeneca/Oxford Covid-19 vaccine must be given a jab from a different producer for his or her second dose.
The HAS mentioned that greater than 500,000 folks under-55s would now get an mRNA vaccine – the Pfizer-BioNTech or Moderna vaccine – as their booster.
French President Emmanuel Macron on Friday defended France’s resolution to restrict the AstraZeneca vaccine to these over 55, pending additional investigation into uncommon blood clotting in some youthful recipients.
However he burdened France was sustaining its vaccine insurance policies total, to guard folks “most in danger.”
Talking throughout a go to to a French manufacturing unit that began bottling and packaging Pfizer-BioNTech vaccines this week, he additionally promised that France would produce 250 million vaccine doses this yr for home and international use.
Macron additionally acknowledged that the US “gained the guess” on coronavirus vaccines by investing massively and shifting quick with experimental remedies, and urged his compatriots to affix a “nationwide warfare effort” to manage and make vaccines.